Cargando…

Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals

SIMPLE SUMMARY: Owing to pegylated interferon (PegIFN)-free direct-acting antivirals (DAAs) against chronic hepatitis C virus infection, a sustained virological response (SVR) rate >95% can be attained with a satisfactory tolerability and shorter treatment duration. However, it still remains cont...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Hye Won, Han, Dai Hoon, Shin, Hye Jung, Lee, Jae Seung, Kim, Seung Up, Park, Jun Yong, Kim, Do Young, Ahn, Sang Hoon, Kim, Beom Kyung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698608/ https://www.ncbi.nlm.nih.gov/pubmed/33217965 http://dx.doi.org/10.3390/cancers12113414

Ejemplares similares

Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy
por: Lee, Jae Seung, et al.
Publicado: (2021)

Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization
por: Kim, Yuna, et al.
Publicado: (2021)

Clinical characteristics and prognosis of Korean patients with hepatocellular carcinoma with respect to etiology
por: Jang, Wonjoon, et al.
Publicado: (2022)

Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals
por: Lee, Hye Won, et al.
Publicado: (2019)

Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization
por: Kim, David Sooik, et al.
Publicado: (2021)

Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals
por: Lee, Hye Won, et al.
Publicado: (2019)

Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy
por: Chang, Jin Won, et al.
Publicado: (2021)

Author Correction: Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals
por: Lee, Hye Won, et al.
Publicado: (2019)

Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation
por: Yun, Byung-Yoon, et al.
Publicado: (2020)

A Case of Lymphocyte-Rich Hepatocellular Carcinoma in a Patient Who Was Treated for Colon Cancer
por: Song, Jae Won, et al.
Publicado: (2021)

Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B
por: Jeon, Mi Young, et al.
Publicado: (2021)

The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
por: Lee, Hye Won, et al.
Publicado: (2021)

Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion
por: Han, Sojung, et al.
Publicado: (2020)

Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis
por: Lee, Jae Seung, et al.
Publicado: (2022)

Predictive validation of qualitative fibrosis staging in patients with chronic hepatitis B on antiviral therapy
por: Lee, Hye Won, et al.
Publicado: (2019)

Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
por: Lee, Jae Seung, et al.
Publicado: (2021)

Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib
por: Lee, Sangheun, et al.
Publicado: (2015)

A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea
por: Lee, Jae Seung, et al.
Publicado: (2020)

Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma
por: Park, Yehyun, et al.
Publicado: (2019)

Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients
por: Kim, David Sooik, et al.
Publicado: (2021)

Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection
por: Jeon, Mi Young, et al.
Publicado: (2019)

Conditional survival estimate in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with/without concurrent radiotherapy
por: Cho, In Rae, et al.
Publicado: (2017)

Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status
por: Kim, Mi Na, et al.
Publicado: (2019)

Transient Elastography is Superior to FIB-4 in Assessing the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B
por: Kim, Seung Up, et al.
Publicado: (2016)

Risk stratification using sarcopenia status among subjects with metabolic dysfunction‐associated fatty liver disease
por: Chun, Ho Soo, et al.
Publicado: (2021)

Use of transient elastography to predict de novo recurrence after radiofrequency ablation for hepatocellular carcinoma
por: Lee, Sang Hoon, et al.
Publicado: (2015)

External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study
por: Lee, Jae Seung, et al.
Publicado: (2022)

Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma
por: Seo, Sang Hyun, et al.
Publicado: (2023)

Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection
por: Kim, Hye Soo, et al.
Publicado: (2020)

Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B
por: Park, Mi Sung, et al.
Publicado: (2013)

Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase
por: Lee, Hye Won, et al.
Publicado: (2020)

Comparison of the Effects of Telbivudine and Entecavir Treatment on Estimated Glomerular Filtration Rate in Patients with Chronic Hepatitis B
por: Lee, Sangheun, et al.
Publicado: (2015)

Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma
por: Lee, Sangheun, et al.
Publicado: (2013)

Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation
por: Kim, Chang Gon, et al.
Publicado: (2019)

Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis
por: Park, Jihye, et al.
Publicado: (2017)

Serum Dickkopf-1 as a Biomarker for the Diagnosis of Hepatocellular Carcinoma
por: Kim, Seung Up, et al.
Publicado: (2015)

Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir
por: Kim, David Sooik, et al.
Publicado: (2019)

Eosinophilic Airway Inflammation and Airway Hyperresponsiveness According to Aeroallergen Sensitization Pattern in Patients With Lower Airway Symptoms
por: Jo, Eun-Jung, et al.
Publicado: (2014)

Validation of PH and Varices Risk Scores for Prediction of High-Risk Esophageal Varix and Bleeding in Patients with B-Viral Cirrhosis
por: Shin, Seunghwan, et al.
Publicado: (2022)

Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria
por: Lee, Jae Seung, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l64eb20isia9nptuhj3n1aaid0